Neuraxis, Inc. (NRXS)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $76.93M
Last updated: Nov 17, 2026 at 11:06 AM ET
Neuraxis, Inc. (NRXS) Stock Forecast
Analysts expect Neuraxis (NRXS) to earn -$0.81 per share in the fiscal year ending Dec 31, 2026, on revenue of $7.80M. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.56.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 101.3%.
- Fiscal year ending Dec 31, 2026
- -$0.81
- EPS consensus, revenue $7.80M
- Fiscal year ending Dec 31, 2027
- -$0.56
- EPS consensus, revenue $15.70M
- Next report
- Mar 17, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.81 | -$0.81 to -$0.81 | 1 | $7.80M | $7.80M to $7.80M | 1 |
| Dec 31, 2027 | -$0.56 | -$0.56 to -$0.56 | 1 | $15.70M | $15.70M to $15.70M | 1 |
Quarterly Estimates
The EPS consensus falls from -$0.12 for the quarter ending Dec 31, 2026 to -$0.19 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.12 | -$0.18 to -$0.06 | 4 | $2.86M | $2.16M to $3.57M | 4 |
| Mar 31, 2027 | -$0.19 | -$0.19 to -$0.19 | 1 | $2.70M | $2.70M to $2.70M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.68.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.81 | -$0.76 | -$0.76 | -$0.76 | -$0.68 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.56 | -$0.27 | -$0.27 | -$0.27 | -$0.06 | N/A |
| Quarter ending Mar 31, 2027 | -$0.19 | -$0.16 | -$0.16 | -$0.16 | -$0.06 | N/A |
Frequently Asked Questions About NRXS
What is the NRXS stock forecast?
Consensus analyst estimates put Neuraxis's EPS at -$0.81 for the fiscal year ending Dec 31, 2026, on revenue of $7.80M.
What EPS do analysts expect from NRXS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.81, with estimates from -$0.81 to -$0.81 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.56, with estimates from -$0.56 to -$0.56 from 1 analyst.
What revenue do analysts expect from Neuraxis next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $7.80M, with estimates from $7.80M to $7.80M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $15.70M, with estimates from $15.70M to $15.70M.
How many analysts cover NRXS?
1 analyst estimates EPS for Neuraxis for the fiscal year ending Dec 31, 2026.
NRXS pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts